| 摘要 |
PROBLEM TO BE SOLVED: To provide a novel drug composition for treating HCV infection.SOLUTION: The invention relates to a formulation which is a noncrystalline solid dispersion, and which contains a hydrophilic polymer accepted as a medicine and preferably a surfactant accepted as a medicine in an HCV inhibitor selected from telaprevir, BI-201335, TMC-435, vaniprevir, MK-5172, asunaprevir, daclatasvir, danoprevir, setrobuvir, tegobuvir, GS-9451, mericitabine, IDX-184, filibuvir, PSI-7977, PSI-352938, BIT-225, boceprevir, GS-5885 or GS-9256. For example, the hydrophilic polymer is a homopolymer or copolymer of N-vinylpyrrolidone, and the surfactant is D-alpha-tocopheryl polyethylene glycol 1000 succinate. |
